NEW YORK (TheStreet) -- Two research firms offered differing views on Nu Skin Enterprises (NUS - Get Report) this morning, with JPMorgan saying it expects the company's results to be hurt by the outbreak of MERS in South Korea while Citi acknowledged concerns about MERS and volatility in China, but still recommends buying the stock.
WHAT'S NEW: JPMorgan analyst John Faucher cut his 2015 and 2016 EPS estimates on the personal care and nutritional products seller by about 4% on concerns that its business will be hurt by the outbreak of Middle East Respiratory Syndrome, or MERS, in South Korea and other areas of Asia. Faucher said the "main bull case" for the stock has been that its results will improve in the second half, but warned that its improvement later in the year could be jeopardized by the disease scare as well as by economic volatility impacting China. The analyst lowered his price target for Nu Skin shares to $49 from $60 and kept a Neutral rating on the stock. Citi's Beth Kite attributed the 10% drop in Nu Skin shares since mid-June to investor worries about MERS and fears about lower consumer spending in China. However, she also noted that Nu Skin is "finally" set to launch Me and Youth, which she expects will drive representative growth. Kite, who was also positive on Nu Skin's appointment of a former Avon (AVP - Get Report) executive to its board, trimmed her price target on the stock to $55 but maintains a Buy rating.
PRICE ACTION: Shares of Nu Skin fell 2% in early trading to $42.30. The weakness comes amid broad strength in the S&P 500, which was up more than 1% soon after the opening bell.
Reporting by Jason Keil.